The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: BEZ235 Trial in Patients With Advanced Endometrial Carcinoma
Official Title: A Phase II, Single-arm Study of Orally Administered BEZ235 as Second-line Therapy in Patients With Advanced or Metastatic Endometrial Carcinoma
Study ID: NCT01290406
Brief Summary: This is an open label and single arm study to investigate the safety and efficacy of BEZ235 in adult women with endometrial carcinoma whose disease progressed (or recurred) while on or after first-line antineoplastic treatment for advanced endometrial carcinoma.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States
Highlands Oncology Group, Fayetteville, Arkansas, United States
City of Hope Medical center, Duarte, California, United States
Holy Cross Hospital, Silver Spring, Maryland, United States
Henry Ford Hospital, Detroit, Michigan, United States
Morriswon Memorial Hospital, Morristown, New Jersey, United States
Carolinas Healthcare Systems, Charlotte, North Carolina, United States
Cancer Centers of North Carolina, Raleigh, North Carolina, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
GHS, Danville, Pennsylvania, United States
Sarah Gautam Rau, Nashville, Tennessee, United States
Texas Oncology, P.A., Austin, Texas, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
STOH, San Antonio, Texas, United States
Pacific Gynecology Specialists, Seattle, Washington, United States
Cancer Care Northwest, Spokane, Washington, United States
Novartis Investigative Site, Rio de Janeiro, , Brazil
Novartis Investigative Site, Sao Paulo, , Brazil
Novartis Investigative Site, Hamilton, , Canada
Novartis Investigative Site, Montreal, , Canada
Novartis Investigative Site, Toronto, , Canada
Novartis Investigative Site, Vancouver, , Canada
Novartis Investigative Site, Bordeaux, , France
Novartis Investigative Site, Caen Cedex, , France
Novartis Investigative Site, La Roche sur Yon Cedex, , France
Novartis Investigative Site, Le Mans, , France
Novartis Investigative Site, Lyon, , France
Novartis Investigative Site, Marseille, , France
Novartis Investigative Site, Nice, , France
Novartis Investigative Site, Paris, , France
Novartis Investigative Site, Saint-Brieuc, , France
Novartis Investigative Site, Toulouse Cedex 3, , France
Novartis Investigative Site, Berlin, , Germany
Novartis Investigative Site, Freiburg, , Germany
Novartis Investigative Site, Jena, , Germany
Novartis Investigative Site, Koln, , Germany
Novartis Investigative Site, Lubeck, , Germany
Novartis Investigative Site, Mainz, , Germany
Novartis Investigative Site, Munchen, , Germany
Novartis Investigative Site, Aviano, , Italy
Novartis Investigative Site, Barcelona, , Italy
Novartis Investigative Site, Bologna, , Italy
Novartis Investigative Site, Brescia, , Italy
Novartis Investigative Site, Capmobso, , Italy
Novartis Investigative Site, Milano, , Italy
Novartis Investigative Site, Modena, , Italy
Novartis Investigative Site, Napoli, , Italy
Novartis Investigative Site, Roma, , Italy
Novartis Investigative Site, Aichi, , Japan
Novartis Investigative Site, Hyogo, , Japan
Novartis Investigative Site, Tokyo, , Japan
Novartis Investigative Site, Sroda Wielkopolska, , Poland
Novartis Investigative Site, Warzawa, , Poland
Novartis Investigative Site, St. Petersburg, , Russian Federation
Novartis Investigative Site, Singapore, , Singapore
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Oviedo, , Spain
Novartis Investigative Site, Valencia, , Spain
Novartis Investigative Site, Istanbul, , Turkey
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR